BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Defects in DNA damage repair (DDR) pathways are prevalent in various cancers, including epithelial ovarian cancer (EOC) and prostate cancer.
• Hereditary predisposition, particularly pathogenic variants (PVs) in BRCA1 and BRCA2, is significant in EOC.
• DDR alterations are more common in metastatic prostate cancer than in localized disease, highlighting the role of genomic instability.

Purpose of the Study:

• To review the mechanisms of DNA damage repair (DDR) and its implications in ovarian and prostate cancers.
• To explore the therapeutic potential of poly (ADP-ribose) polymerase (PARP) inhibitors in these malignancies.
• To discuss the importance of genomic analysis and the need for predictive biomarkers for PARP inhibitor treatment response.

Main Methods:

• Review of existing literature on DNA damage repair mechanisms.
• Analysis of genetic testing data in ovarian and prostate cancer patients.
• Examination of the development and application of PARP inhibitors.

Main Results:

• PARP inhibitors exploit synthetic lethality, showing high efficacy in tumors with BRCA1/BRCA2 mutations.
• The therapeutic potential of PARP inhibitors extends beyond germline BRCA mutations to broader homologous recombination deficiency (HRD).
• PARP inhibitors are advancing in clinical development for metastatic castration-resistant prostate cancer.

Conclusions:

• Exploiting DDR defects through PARP inhibitors represents a promising therapeutic strategy for ovarian and prostate cancers.
• Genomic analysis is crucial for patient stratification and treatment selection.
• Development of reliable predictive biomarkers is essential to optimize PARP inhibitor therapy and improve patient outcomes.